TY - JOUR
T1 - Variation in process quality measures of diabetes care by region and institution in Japan during 2015–2016
T2 - An observational study of nationwide claims data
AU - Sugiyama, Takehiro
AU - Imai, Kenjiro
AU - Ihana-Sugiyama, Noriko
AU - Tanaka, Hirokazu
AU - Yanagisawa-Sugita, Ayako
AU - Sasako, Takayoshi
AU - Higashi, Takahiro
AU - Okamura, Tomonori
AU - Yamauchi, Toshimasa
AU - Ueki, Kohjiro
AU - Ohsugi, Mitsuru
AU - Kadowaki, Takashi
N1 - Funding Information:
We appreciate helpful comments from the members of the research team: Dr. Naoki Kashihara (Kawasaki Medical University, Japan), Dr. Issei Komuro (the University of Tokyo, Japan), Dr. Yuichiro Ogura (Nagoya City University, Japan), Dr. Hirokazu Okada (Saitama Medical University, Japan), Dr. Koichi Node (Saga University, Japan), Dr. Toshinori Murata (Shinshu University, Japan), Dr. Naoki Nakashima (Kyushu University, Japan), Dr. Tooru Kikuchi (Saitama Medical University, Japan), Dr. Naoko Tajima (Jikei University, Japan), Dr. Masaomi Nangaku (the University of Tokyo, Japan), Dr. Hidemi Takimoto (National Institutes of Biomedical Innovation, Health and Nutrition, Japan), Dr. Hiroshi Akazawa (the University of Tokyo, Japan), Dr. Ryo Kawasaki (Osaka University, Japan), Dr. Takumi Hirata (Tohoku University, Japan), Dr. Daisuke Sugiyama (Keio University, Japan), Dr. Atsushi Tanaka (Saga University, Japan), Dr. Shun Kosaka (Keio University, Japan), Dr. Tetsuhiro Tanaka (the University of Tokyo, Japan) and Dr. Shinji Kume (Shiga University, Japan). We also thank Dr. Yasuki Kobayashi (the University of Tokyo, Japan), Dr. Mitsuhiko Noda (Saitama Medical University, Japan), Dr. Yasuyuki Okumura (Tokyo Metropolitan Institute of Medical Science, Japan) and Ms. Tomone Watanabe (National Cancer Center, Japan) for their helpful comments, Dr. Koichi B. Ishikawa (International University of Health and Welfare, Japan) for providing the variable lists, and Ms. Kayuri Auld-Fujiwara (National Center for Global Health and Medicine, Japan) and Ms. Moe Nakanishi (National Center for Global Health and Medicine, Japan) for their data-collecting contribution. We would like to thank Enago (www.enago.jp) for the English language review. The data that support the findings of this study (an extract from the NDB) are available from the Ministry of Health, Labour, and Welfare, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Please contact T.Su (tsugiyama-tky@umin.ac.jp) if further clarification is needed. This study was supported by Health and Labour Sciences Research Grants (Comprehensive Research on Life-Style Related Diseases including Cardiovascular Diseases and Diabetes Mellitus, H29-Cardiovascular-General-004, PI: Dr. Takashi Kadowaki). The funding agency had no role in the design or conduct of the study; collection, management, analysis, and interpretation of data; preparation, review or approval of the manuscript; and the decision to submit the manuscript for publication. A part of the present study was presented orally at the 61st Annual Meeting of the Japan Diabetes Society on May 24th, 2018 (Tokyo, Japan). T.Su. K.I. N,S,-I, T.Sa, T.Y. M.O. and T.K. designed the study. T.Su. and K.I. acquired data. T.Su. and N.S.-I. analysed data. T.Su. K.I. N.S.-I, H.T. A.S.-Y. T.Sa. T.H. T.O. T.Y. K.U. M.O. and T.K. interpreted data. T.Su. drafted the manuscript. K.I. N.S.-I, H.T. A.S.-Y. T.Sa. T.H. T.O. T.Y. K.U. M.O. and T.K. critically revised the draft. T. Su. M.O. and T.K. are the guarantors of this work, and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The authors complied with the RECORD statement (ESM Table 7). None.
Funding Information:
This study was supported by Health and Labour Sciences Research Grants (Comprehensive Research on Life-Style Related Diseases including Cardiovascular Diseases and Diabetes Mellitus, H29-Cardiovascular-General-004, PI: Dr. Takashi Kadowaki). The funding agency had no role in the design or conduct of the study; collection, management, analysis, and interpretation of data; preparation, review or approval of the manuscript; and the decision to submit the manuscript for publication.
Publisher Copyright:
© 2019 The Authors
PY - 2019/9
Y1 - 2019/9
N2 - Aims: To calculate process quality measures of diabetes care in Japan using nationwide exclusive claims database. Methods: Using the National Database of health insurance claims during 2015–2016, the proportions of outpatients who received recommended examinations at least annually among those with regular antidiabetic medication were calculated as quality indicators, reported altogether and by prefecture and institutional certification (from the Japan Diabetes Society). Distributions of institutional-level quality indicators were also reported. Results: Among 4,154,452 outpatients, 96.7% underwent HbA1c or glycated albumin examination. Retinopathy examination was conducted among 46.5% of patients [prefecture (range): 37.5%–51.0%, institutional certification: 44.8% (without) vs. 59.8% (with)]. Urinary qualitative examination was conducted among 67.3% of patients at institutions with <200 beds (prefecture: 54.1%–81.9%, institutional certification: 66.8% vs. 92.8%), whereas urinary quantitative albumin or protein examination was conducted among 19.4% of patients (prefecture: 10.8%–31.6%, institutional certification: 18.7% vs. 54.8%). Distributions of institutional-level quality indicators showed that most institutions without institutional certification seldomly order urinary quantitative examination. Conclusions: Although the quality indicator for glycaemic control examination was favourable, some aspects of diabetes care were suboptimal and varied greatly by prefecture and institution; individual and organisational efforts to improve quality of diabetes care would be needed in Japan.
AB - Aims: To calculate process quality measures of diabetes care in Japan using nationwide exclusive claims database. Methods: Using the National Database of health insurance claims during 2015–2016, the proportions of outpatients who received recommended examinations at least annually among those with regular antidiabetic medication were calculated as quality indicators, reported altogether and by prefecture and institutional certification (from the Japan Diabetes Society). Distributions of institutional-level quality indicators were also reported. Results: Among 4,154,452 outpatients, 96.7% underwent HbA1c or glycated albumin examination. Retinopathy examination was conducted among 46.5% of patients [prefecture (range): 37.5%–51.0%, institutional certification: 44.8% (without) vs. 59.8% (with)]. Urinary qualitative examination was conducted among 67.3% of patients at institutions with <200 beds (prefecture: 54.1%–81.9%, institutional certification: 66.8% vs. 92.8%), whereas urinary quantitative albumin or protein examination was conducted among 19.4% of patients (prefecture: 10.8%–31.6%, institutional certification: 18.7% vs. 54.8%). Distributions of institutional-level quality indicators showed that most institutions without institutional certification seldomly order urinary quantitative examination. Conclusions: Although the quality indicator for glycaemic control examination was favourable, some aspects of diabetes care were suboptimal and varied greatly by prefecture and institution; individual and organisational efforts to improve quality of diabetes care would be needed in Japan.
KW - Claims data
KW - Diabetes
KW - Health services research
KW - Japan
KW - Quality of care
UR - http://www.scopus.com/inward/record.url?scp=85069723038&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069723038&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2019.05.029
DO - 10.1016/j.diabres.2019.05.029
M3 - Article
C2 - 31229599
AN - SCOPUS:85069723038
SN - 0168-8227
VL - 155
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
M1 - 107750
ER -